|1.||Vermeer, Cees: 2 articles (01/2015 - 09/2012)|
|2.||Schurgers, Leon J: 2 articles (01/2015 - 09/2012)|
|3.||Yamaguchi, Masayoshi: 2 articles (11/2006 - 03/2003)|
|4.||Tsukamoto, Yoshinori: 2 articles (01/2004 - 03/2003)|
|5.||Kim, Min Seuk: 1 article (10/2015)|
|6.||Ahn, Byung-Yong: 1 article (10/2015)|
|7.||Wu, Wei-Jie: 1 article (10/2015)|
|8.||Ahmed, Sameh: 1 article (08/2015)|
|9.||Alkady, Eman A M: 1 article (08/2015)|
|10.||Abdel-Rahman, Mahran S: 1 article (08/2015)|
01/01/2004 - "Studies on action of menaquinone-7 in regulation of bone metabolism and its preventive role of osteoporosis."
05/01/2006 - "Japanese fermented soybeans (natto in Japanese), which contain a large amount of menaquinone-7, may help prevent the development of osteoporosis. "
02/01/2014 - "A nutritional food rich in menaquinone-7 has a potential in preventing osteoporosis and cardiovascular diseases. "
03/01/1995 - "These results suggest the possibility that deficiency of vitamin K, particularly that of menaquinone-7, is one of the risk factors for developing osteoporosis."
|2.||Vitamin K Deficiency
|3.||Hip Fractures (Intertrochanteric Fractures)
08/01/2001 - "Circulating levels of vitamin K1, menaquinone-4, and menaquinone-7 in healthy elderly Japanese women and patients with vertebral fractures and patients with hip fractures."
08/01/2001 - "In this study, we measured circulating levels of vitamin K1, menaquinone-4 (MK-4) and menaquinone-7 (MK-7) in 23 normal healthy women aged 52-93 years (mean +/- SD: 80.1 +/- 3.5), 13 female patients with vertebral fractures aged 66-93 years (80.3 +/- 7.8) and 38 female patients with hip fractures aged 76-87 years (79.8 +/- 9.2), (all Japanese), in order to make sure whether these vitamin K levels were different in these three groups. "
|4.||Coronary Artery Disease (Coronary Atherosclerosis)
|5.||Body Weight (Weight, Body)
09/28/2012 - "The effects of vitamin K treatment on adiponectin, body weight and BMI were investigated in archived samples from forty-two young men and women who received varying doses of menaquinone-7 during 12 weeks (study II) and from a cohort of 164 postmenopausal women who participated in a 3-year placebo-controlled trial on 45 mg menaquinone-4 (MK-4) (study III). "
|3.||Vitamin K 2 (Vitamin K2)
|5.||Vitamin K 1 (Phylloquinone)